Search results for " Pharmaceutical"

showing 10 items of 409 documents

Development and characterization of co-loaded curcumin/triazole-halloysite systems and evaluation of their potential anticancer activity.

2014

Abstract Positively charged halloysite nanotubes functionalized with triazolium salts (f-HNT) were employed as a carrier for curcumin molecules delivery. The synthesis of these f-HNT new materials is described. Their interaction with curcumin was evaluated by means dynamic light scattering (DLS) and UV–vis spectroscopy in comparison with pristine unmodified HNT (p-HNT). The curcumin load into HNT was estimated by thermogravimetric analysis (TGA) measurements, while the morphology was investigated by scanning electron microscopy (SEM) techniques. Release of curcumin from f-HNT, at three different pH values, by means of UV–vis spectroscopy was also studied. Furthermore, different cancer cell …

Thermogravimetric analysisCurcuminCell SurvivalScanning electron microscopeTriazolePharmaceutical ScienceAntineoplastic Agentsengineering.materialHalloysiteSettore MED/13 - EndocrinologiaDrug Incompatibilitychemistry.chemical_compoundhalloysite nanotubes triazolium salts drug carrier curcumin in vitro anticancer activityDynamic light scatteringCell Line TumorHumansTechnology PharmaceuticalOrganic chemistrySolubilityCell ProliferationSettore CHIM/02 - Chimica FisicaDrug CarriersNanotubesSettore CHIM/06 - Chimica OrganicaTriazolesDrug LiberationchemistryThermogravimetryMicroscopy Electron ScanningengineeringCurcuminClayAluminum SilicatesDrug carrierNuclear chemistry
researchProduct

A new biodegradable and biocompatible hydrogel with polyaminoacid structure

2007

The preparation and physicochemical and biological characterization of a novel polyaminoacid hydrogel have been reported. The ,-poly(N-2- hydroxyethyl)-dl-aspartamide (PHEA) has been used as a starting polymer for a derivatization reaction with methacrylic anhydride (MA) to give rise to the methacrylate derivative named PHM. Photocrosslinking of PHM has been performed in aqueous solution at 313 nm and in the absence of toxic initiators. PHM-based hydrogel has been characterized by scanning electron microscopy, X-ray diffractometry, swelling measurements in aqueous media; the degradation of PHM-based hydrogel has been evaluated as a function of time in the absence or in the presence of ester…

Time FactorsBiocompatibilityCell SurvivalSurface PropertiesChemistry PharmaceuticalPharmaceutical ScienceMethacrylic anhydrideBiocompatible MaterialsMicroscopy Atomic ForceMethacrylateDosage formchemistry.chemical_compoundPolymethacrylic AcidsX-Ray DiffractionSpectroscopy Fourier Transform InfraredPolymer chemistryHumansTechnology PharmaceuticalDrug CarriersAqueous solutionHydrolysisEsterasestechnology industry and agricultureWaterHydrogelshydrogels FT-IRBlood ProteinschemistrySelf-healing hydrogelsDrug deliveryMicroscopy Electron ScanningK562 CellsPeptidesDrug carrierPorosityProtein BindingNuclear chemistryInternational Journal of Pharmaceutics
researchProduct

SYNTHESIS, CHARACTERIZATION AND IN VITRO CYTOTOXICITY STUDIES OF A MACROMOLECULAR CONJUGATE OF PACLITAXEL BEARING OXYTOCIN AS TARGETING MOIETY.

2007

The present study describes the experimental synthetic procedure and the characterization of a new polyaspartamide macromolecular prodrug of paclitaxel, bearing oxytocin residues as targeting moieties. In vitro stability studies of bioconjugate, performed in media mimicking biological fluids (buffer solutions at pH 7.4 and 5.5) and in human plasma, evidenced the high stability of the targeting portion (oxytocin)-polymer linkage and the ability of this conjugate to release linked paclitaxel in a prolonged way in plasma. Moreover, preliminary in vitro antiproliferative studies, carried out on MCF-7 cells, that are oxytocin receptor positive cells, showed that the polymeric conjugate has the s…

Time FactorsChemistry PharmaceuticalDrug CompoundingpolyaspartamidePharmaceutical ScienceBreast NeoplasmsPolyethylene Glycolschemistry.chemical_compoundpaclitaxelDrug StabilityCell Line TumoroxytocinHumansMoietyProdrugsbioconjugateCytotoxicityCell ProliferationDrug CarriersDose-Response Relationship DrugMolecular StructureHydrolysisdrug targetingGeneral MedicineHydrogen-Ion ConcentrationAntineoplastic Agents PhytogenicOxytocin receptorIn vitroSolubilityPaclitaxelchemistryBiochemistryTargeted drug deliveryReceptors OxytocinDelayed-Action PreparationsFemalePeptidesDrug carrierBiotechnologyConjugate
researchProduct

Nortriptyline for smoking cessation: Release and human skin diffusion from patches

2009

Abstract The objective of this work was to develop a simple and inexpensive transdermal formulation containing Nortriptyline Hydrochloride (NTH) for smoking cessation support therapy. Hydroxypropyl-methyl-cellulose was chosen as polymer and a mixture of transdermal enhancers (selected from previous research) was incorporated. The formulations were characterised in terms of appearance, thickness, uniformity of NTH content, release and skin permeation. Release studies demonstrated controlled release for four formulations. Diffusion studies were performed through human heat separated epidermis (HHSE) using Franz Diffusion Cells (FDC). Patches provided different fluxes varying from 20.39 ± 7.09…

Time FactorsChemistry PharmaceuticalSkin AbsorptionPharmaceutical ScienceHuman skinNortriptylineIn Vitro TechniquesAdministration CutaneousPermeabilityDosage formExcipientsStratum corneummedicineHumansTransdermalMicroscopy ConfocalChromatographyAdrenergic Uptake Inhibitorsintegumentary systembusiness.industryPenetration (firestop)PermeationControlled releasemedicine.anatomical_structureNortriptyline HydrochlorideAnesthesiaMethacrylatesFemaleSmoking CessationbusinessInternational Journal of Pharmaceutics
researchProduct

Photo-Cross-Linked Hydrogels with Polysaccharide−Poly(amino acid) Structure:  New Biomaterials for Pharmaceutical Applications

2006

The aim of this work has been the preparation and characterization of novel hydrogels with polysaccharide-poly(amino acid) structure having suitable physicochemical properties for pharmaceutical applications. In the first step, hyaluronic acid (HA) and alpha,beta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) have been derivatized with methacrylic anhydride (AMA), thus obtaining HA-AMA and PHM derivatives, respectively. In the second step, aqueous solutions of both these derivatives have been irradiated at 313 nm to obtain chemical hydrogels. The hydrogel obtained by irradiating for 15 min an aqueous solution containing 4% w/v of HA-AMA and 4% w/v of PHM resulted in the highest yield. Its swe…

Time FactorsPolymers and PlasticsUltraviolet RaysChemistry PharmaceuticalMolecular Sequence DataMethacrylic anhydrideBiocompatible MaterialsBioengineeringmacromolecular substancesBiomaterialschemistry.chemical_compoundPolysaccharidesPolymer chemistryCarbohydrate ConformationMaterials ChemistryAmino Acidschemistry.chemical_classificationAqueous solutionChemistrytechnology industry and agricultureChemical modificationHydrogelsAmino acidCarbohydrate Sequencebiomaterials drug delivery hyaluronic acidDrug deliverySelf-healing hydrogelsLiberationDrug carrierNuclear chemistryBiomacromolecules
researchProduct

Prostaglandin E(2)-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release.

2008

PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by periton…

Time Factorsmedicine.medical_treatmentPhagocytosisChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceInflammationPharmacologyBiologyNitric OxideDinoprostonechemistry.chemical_compoundMiceImmune systemPhagocytosisIn vivoSepsismedicineAnimalsHumansImmunologic FactorsProstaglandin E2Particle SizeCells CulturedChemokine CCL2Tumor Necrosis Factor-alphaEndothelial CellsWaterGeneral MedicineMicrospheresDisease Models AnimalchemistryBiochemistrySolubilityDelayed-Action PreparationsMacrophages PeritonealLiberationlipids (amino acids peptides and proteins)Arachidonic acidEmulsionsmedicine.symptomInflammation MediatorsOilsBiotechnologyProstaglandin Emedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.

2017

Here, nano into micro formulations (NiMs) of tobramycin for the treatment of Pseudomonas aeruginosa airway infections in cystic fibrosis (CF) are described. NiMs were produced by spray drying a solution containing polymers or sugars and a nanometric polyanion–tobramcyin complex (PTC), able to achieve a prolonged antibiotic release. NiMs properties were compared to TOBIPodhaler(Novartis), the only one commercially available dry powder inhalatory formulation based on porous microparticles. Produced NiMs showed adequate characteristics for pulmonary administration, as spherical shape, micrometric size, and high cytocompatibility toward human bronchial epithelial cells. Contrarily to TOBIPodhal…

Tobramycin Cystic Fibrosis Artificial Mucus (CF-AM) αβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) ion pair complex nano into micro strategy Pseudomonas aeruginosa infections biofilmPolymers and PlasticsCystic FibrosisPolymersChemistry PharmaceuticalBioengineeringBronchi02 engineering and technologymedicine.disease_causeCystic fibrosisMicrobiologyBiomaterials03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNano-Materials ChemistrymedicineTobramycinHumansPseudomonas InfectionsParticle SizeRespiratory Tract InfectionsCells CulturedDrug CarriersPseudomonas aeruginosaChemistryBiofilmDry Powder InhalersEpithelial Cells021001 nanoscience & nanotechnologyAntimicrobialmedicine.diseaseMucusPolyelectrolytesAnti-Bacterial Agents030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSpray dryingBiofilmsDelayed-Action PreparationsPseudomonas aeruginosaTobramycinNanoparticles0210 nano-technologymedicine.drugBiomacromolecules
researchProduct

Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.

2004

1. A study performed > 10 years ago and case reports published recently suggest that triclabendazole is effective for the treatment of patients with fascioliasis. 2. To confirm the efficacy of a human formulation of triclabendazole, we enrolled 165 patients into the present study and divided the subjects into two groups: (i) those who had fascioliasis, as evidenced by the presence of ova in their stools; and (ii) patients with clinical and laboratory data suggesting fascioliasis. 3. Patients were randomly allocated to receive 10 mg/kg, p.o., triclabendazole for 1, 2 or 3 days (single-, double- and triple-dose groups, respectively). Medical history and physical and laboratory examinations we…

Toxic hepatitisAdultMalemedicine.medical_specialtyCure rateFascioliasisAdolescentPhysiologyChemistry PharmaceuticalGastroenterologylaw.inventionFecesRandomized controlled triallawOral administrationPhysiology (medical)Internal medicineMedicineHumansMedical historyIn patientChildTriclabendazoleAgedPharmacologyAnthelminticsDose-Response Relationship Drugbusiness.industryMiddle AgedSurgeryTriclabendazoleTreatment OutcomeHuman fascioliasisImmunoglobulin GBenzimidazolesFemalemedicine.symptombusinessmedicine.drugClinical and experimental pharmacologyphysiology
researchProduct

Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity

2018

Abstract Pyrrolizinones represent an interesting class of compounds with varied degrees of structural complexity and pharmacological activity. Among these, 9H-pyrido[2,3-b]pyrrolizin-9-one, tripentone analogs, recently reported by us, showed significant antiproliferative activity against human tumor cell lines, inducing apoptosis and not affecting viability of Caco-2 differentiated in normal intestinal-like cells. Considering their interesting biological activity, their 5H-pyrido[3,2-b]pyrrolizin-5-one analogs were efficiently synthesized in good to excellent yields (61–91%). All tripentone derivatives were tested to assess their cytotoxicity against two human tumor cell lines, HCT-116 (hum…

TripentonesPyridinesAntineoplastic AgentsApoptosisAntiproliferative activity5H-pyrido[3; 2-b]pyrrolizin-5-ones; Antiproliferative activity; Antitumor; Apoptosis; Tripentones; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry010402 general chemistry01 natural sciencesStructure-Activity Relationship2-b]pyrrolizin-5-onesCell Line TumorNeoplasmsDrug DiscoverymedicineHumansCytotoxic T cellPyrrolesCytotoxicityMitosisIC505H-pyrido[32-b]pyrrolizin-5-onePharmacology010405 organic chemistryChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic Chemistry5H-pyrido[3ApoptosiTripentoneCancerBiological activityAntitumorGeneral MedicineHCT116 Cellsmedicine.disease0104 chemical sciencesCell cultureApoptosisMCF-7 CellsCancer researchCaco-2 CellsDrug Screening Assays AntitumorEuropean Journal of Medicinal Chemistry
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct